VRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today, the stock price of Valeant Pharmaceuticals International Inc is $96.59. Valeant Pharmaceuticals International Inc's graham number for the quarter that ended in Sep. 2015 was $0.00. Therefore, Valeant Pharmaceuticals International Inc's Price to Graham Number ratio for today is .
During the past 13 years, the highest Price to Graham Number ratio of Valeant Pharmaceuticals International Inc was 22.39. The lowest was 1.17. And the median was 3.58.
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Graham Number is a concept based on Ben Graham's conservative valuation of companies.
Valeant Pharmaceuticals International Inc's Graham Number for the fiscal year that ended in Dec. 2014 is calculated as
|=||sqrt of (22.5||*||Tangible Book Value per Share||*||EPS without Non-Recurring Items (NRI))|
|=||sqrt of (22.5||*||-45.72||*||2.675)|
Valeant Pharmaceuticals International Inc's Graham Number for the quarter that ended in Sep. 2015 is calculated as
|=||sqrt of (22.5||*||Tangible Book Value per Share||*||EPS without Non-Recurring Items (NRI) (TTM))|
|=||sqrt of (22.5||*||-97.39||*||1.76)|
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Valeant Pharmaceuticals International Inc's Price to Graham number Ratio for today is calculated as
|Price to Graham number||=||Share Price (Today)||/||Graham number (Q: Sep. 2015 )|
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Earnings per share without Non-Recurring Items (NRI), Intrinsic Value (DCF Projected), Intrinsic Value (DCF), Intrinsic Value (DE), Tangible Book Value per Share, Earnings Per Share, Total Equity, Net Income, Total Shares Outstanding
Valeant Pharmaceuticals International Inc Annual Data
Valeant Pharmaceuticals International Inc Quarterly Data